Skip to main content
Clinical Trials/NCT04290559
NCT04290559
Unknown
Not Applicable

Long-term Monitoring After Persistent Atrial Fibrillation Ablation and Correlation to Quality of Life

Newmarket Electrophysiology Research Group Inc1 site in 1 country200 target enrollmentSeptember 10, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Newmarket Electrophysiology Research Group Inc
Enrollment
200
Locations
1
Primary Endpoint
AF burden correlated with change in QOL.
Last Updated
6 years ago

Overview

Brief Summary

The primary objective of this study is to determine the atrial fibrillation burden reduction, or absolute atrial fibrillation burden, associated with improvement in quality of life in patients undergoing ablation of persistent atrial fibrillation.

Detailed Description

Atrial fibrillation (AF) is associated with a higher risk of stroke, heart failure and deterioration in patients' quality of life and it also has great effect on health care resource utilization due to increasing morbidity and mortality. Catheter ablation has shown to improve patients' quality of life (QOL), even in those who undergo a repeat procedure, equalizing healthy population and lowering subsequent health care resource utilization. Success rates are usually based on an endpoint of total elimination of AF, typically absence of any AF recurrence \>30 seconds. While this is a high standard for clinical trial reporting, it does not necessarily measure the "clinical" success, since many patients will experience significant reduction in their AF burden with accompanying improvement in their functional status despite having ongoing brief recurrences of AF. This is a prospective non-randomized, single-arm, cohort study. 200 patients with persistent atrial fibrillation undergoing catheter ablation will be enroled. AF burden post procedure will be evaluated with continuous monitoring with an implantable loop recorder (ILR) to assess recurrences and AF burden. QOL will be measured using the CCS-SAF severity scale, SF-36 and AFEQT scales pre-ablation and at 12 and 24 months.

Registry
clinicaltrials.gov
Start Date
September 10, 2018
End Date
September 2022
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Newmarket Electrophysiology Research Group Inc
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \> 18 years
  • Patients undergoing first-time or redo AF ablation.
  • Persistent or long-standing persistent AF
  • Symptomatic atrial fibrillation
  • Willing and able to provide informed consent.
  • Willing and able to set up and utilize MyCareLink® home monitor and be remotely monitored
  • Atrial fibrillation burden equal or more than 80% prior to the ablation

Exclusion Criteria

  • Paroxysmal AF
  • If the patient has had a cardioversion within 2 months of the ablation
  • Patients with contraindication to oral or intravenous anticoagulation.
  • Contraindication to implantation of an ILR

Outcomes

Primary Outcomes

AF burden correlated with change in QOL.

Time Frame: 12 months, 24 months

AF burden change and absolute AF burden correlated with change in QOL mesured at 12 and 24 months after the AF ablation

Secondary Outcomes

  • Freedom of atrial arrhythmia(12 months, 24 months)
  • Incidence of silent AF recurrences(12 months, 24 months)
  • Economic evaluation(12 months, 24 months)
  • Impact of antiarrhythmic treatment(12 months)

Study Sites (1)

Loading locations...

Similar Trials